[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-adenocarcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,55,79,103,127,156,184,207,246,275,302,330,360,394,424],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100603974","family-communications-after-genetic-testing-100603974",false,"NCT07143487","Family Communications After Genetic Testing","Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer","Inclusion Criteria:\n\n* STEP 1 PROBANDS: Age \\>= 18 years\n* STEP 1 PROBANDS: Patients with a newly diagnosed (within 3 months of registration), primary colorectal adenocarcinoma, stage I to IV\n\n  * Histologically proven stage I to IV colon or rectal adenocarcinoma (any T or N, M+). Tumors deemed to originate in the colon can extend into\u002Finvolve the small bowel (e.g., those at the ileocecal valve). Tumors will be regarded as originating in the colon if the entire tumor is in the colon. In the case of rectal involvement, the cancer will be considered a rectal primary\n  * Patients with more than one primary colon adenocarcinoma are eligible\n* STEP 1 PROBANDS: No patients with stage 0 or in-situ colorectal cancer\n* STEP 1 PROBANDS: Patients who have had prior malignancies are eligible, including non-invasive cancers\n* STEP 1 PROBANDS: Patients with synchronous second malignancies are eligible\n* STEP 1 PROBANDS: Have not received germline testing in the 2 years prior to enrollment or known hereditary colon cancer syndromes\n* STEP 1 PROBANDS: Patients must have at least 2 living FDRs who meet the eligibility criteria, with whom the patient is willing to share their cancer diagnosis\n* STEP 1 PROBANDS: In order to complete the mandatory patient-completed measures and view the video and receive genetic education and counseling, participants must be able to speak and read English or Spanish\n* STEP 1 PROBANDS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members\n\n  \\* No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician\n* STEP 2 PROBANDS: Probands positive for a pathogenic germline variant (PGV) in a cancer susceptibility gene\n* FDRs: Age \\>= 18 years\n* FDRs: Have not previously received germline genetic testing or known hereditary colon cancer syndromes\n* FDRs: FDRs must reside within the United States, as genetic testing from LabCorp is only available to United States (U.S.) residents\n* FDRs: In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish\n\nExclusion Criteria:\n\n\\-",true,"ALL","18 Years",{"count":20,"type":21},4186,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer susceptibility gene. Most individuals carrying a pathogenic germline variant are unaware of their cancer risk and may not meet guidelines for genetic testing. Identifying pathogenic germline variants or hereditary cancer syndromes in cancer patients has important implications for their at-risk relatives who may not know that they are at high risk for cancer. The burden of communicating this risk to first-degree relatives often falls on the patients, who may lack sufficient knowledge to correctly share and explain their genetic test results. Receiving provider-mediated communication of genetic testing results may be more effective at communicating genetic risk to first-degree relatives than the usual practice of proband-mediated communication.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Colon Adenocarcinoma","Colorectal Adenocarcinoma","Rectal Adenocarcinoma","Stage I Colon Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Rectal Cancer AJCC v8","Stage II Colon Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Rectal Cancer AJCC v8","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","RECRUITING","2026-07-01",{"date":45,"type":46},"2026-07-02","ACTUAL",{"date":48,"type":46},"2026-04-06",{"date":50,"type":21},"2032-11-05",{"name":52,"class":53},"Alliance for Clinical Trials in Oncology","OTHER",276,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100644786","improving-prognostication-in-colon-cancer-100644786","NCT07673393","Improving Prognostication in Colon Cancer","Improving Prognostication of Localised Colon Cancer by Combining Liquid Biopsy and Histology: a Multicentric, Prospective Study","MARBLE","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed primary colon tumor clinically and\u002For histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.\n4. Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.\n5. WHO (ECOG) performance status ≤ 3 at baseline.\n\nExclusion Criteria:\n\n1. Participant has been diagnosed with metastatic disease (Stage IV)\n2. Participant has been diagnosed with rectal cancer\n3. Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)\n4. Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer\n5. Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.\n6. Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.\n7. Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).",{"count":64,"type":21},400,"OBSERVATIONAL","The goal of this study is to test better ways to predict if cancer will return after surgery in adults (18+) who have been diagnosed with stage II or III colon cancer.\n\nThe main questions it aims to answer are:\n\n* Can computer programs (Artificial Intelligence) and special blood tests give more accurate information about the risk of cancer returning than the methods doctors use today?\n* Does combining these new tests help doctors better understand which patients really need chemotherapy and which do not?\n\nResearchers will compare the new computer and blood tests to the standard hospital methods used now to see if the new way is more accurate in predicting the cancer's behavior\n\nParticipants will:\n\n* Sign a form saying they agree to take part in the study\n* Have their standard surgery to remove the tumor\n* Give a few extra teaspoons of blood during their regular, scheduled hospital visits\n* Allow researchers to scan and study a small piece of the tumor that was already removed during surgery\n* Continue with their normal hospital check-ups for up to five years so researchers can track their health",[68,27],"Colon Cancer","NOT_YET_RECRUITING","2026-06-22",{"date":72,"type":46},"2026-06-29",{"date":74,"type":21},"2026-09",{"date":76,"type":21},"2033-09",{"name":78,"class":53},"Universitaire Ziekenhuizen KU Leuven",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100592750","phase-3-a-clinical-study-of-calderasib-mk-1084-with-targeted-therapy-and-chemotherapy-in-people-with-colorectal-cancer-mk-1084-012kandlelit-012-100592750","NCT06997497","A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012\u002FKANDLELIT-012)","A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a histologically confirmed diagnosis of locally advanced unresectable or metastatic (unresectable Stage III or Stage IV as defined by American Joint Committee on Cancer \\[AJCC\\] eighth edition) colorectal adenocarcinoma\n* Part 2 only: Has not received systemic anticancer therapy for locally advanced unresectable or metastatic colorectal cancer; an exception is permitted for 1-2 cycles of FOLFOX or 1 cycle of CAPOX as optional chemotherapy before or during the screening period\n* Demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease\n* Has known partial or complete dihydropyrimidine dehydrogenase (DPD) deficiency\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization, with the exception of the optional chemotherapy\n* Has 1 or more conditions that, in the opinion of the investigator, make the participant ineligible for treatment with bevacizumab\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis or leptomeningeal disease\n* Has active infection requiring systemic therapy\n* Has not adequately recovered from major surgery or have ongoing surgical complications\n* Has a history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease",{"count":87,"type":21},477,[89],"PHASE3","Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.\n\nStandard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies.\n\nThe goals of this study are to learn:\n\n* About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments\n* If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.",[27,29],"2026-06-11",{"date":94,"type":46},"2026-06-15",{"date":96,"type":46},"2025-07-16",{"date":98,"type":21},"2030-10-27",{"name":100,"class":101},"Merck Sharp & Dohme LLC","INDUSTRY",200,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100433123","phase-1-study-of-ctdna-guided-change-in-tx-for-refractory-minimal-residual-disease-in-colon-adenocarcinomas-100433123","NCT04920032","Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas","Inclusion Criteria:\n\n1. Patients must have histologically or cytologically confirmed adenocarcinoma of the colon (high rectal cancer is eligible if resected and no radiation needed). Other histologies which are treated per NCCN guidelines for adjuvant colon cancer are eligible.\n2. Must have Stage II, Stage III, or Stage IV colorectal cancer after curative intent resection eligible for adjuvant doublet chemotherapy for at least 3 months.\n3. Must have ctDNA positive assay (tested by Signatera MRD assay) after at least 3 months of perioperative chemotherapy\n4. Age ≥ 18 years\n5. Performance status: ECOG performance status ≤2\n6. Life expectancy of greater than 3 months\n7. Adequate organ and marrow function as defined below:\n\n   1. leukocytesL ≥ 3,000\u002FmcL\n   2. absolute neutrophil count: ≥ 1,500\u002FmcL\n   3. platelets: ≥ 80,000\u002Fmcl\n   4. total bilirubin: within normal institutional limits\n   5. AST(SGOT)\u002FALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present\n   6. creatinine: \\\u003C1.5 X ULN\n8. The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n   a. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n   * Has not undergone a hysterectomy or bilateral oophorectomy; or\n   * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n9. Ability to swallow tablets\n10. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to Cycle 1 Day 1\n2. All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline\n3. Patients may not be receiving any other investigational agents.\n4. Patients with known metastases.\n5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study.\n6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n7. Prior treatment with TAS-102 at any time or irinotecan within 90 days from enrollment.\n8. History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ.\n9. Inability to comply with study and follow-up procedures as judged by the Investigator\n10. Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. -",{"count":111,"type":21},22,[113],"PHASE1","This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.",[27,116],"Colorectal Cancer","2026-05-06",{"date":119,"type":46},"2026-05-11",{"date":121,"type":46},"2021-08-26",{"date":123,"type":21},"2028-01-21",{"name":125,"class":53},"University of California, Irvine",1,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":126},"100628975","phase-2-tolecizumab-plus-chemoimmunotherapy-for-pmmrmss-locally-advanced-colon-adenocarcinoma-100628975","NCT07468630","Tolecizumab Plus Chemoimmunotherapy for pMMR\u002FMSS Locally Advanced Colon Adenocarcinoma","A Multicenter, Randomized, Open-Label, Blinded-Endpoint Phase II Study of Tolecizumab (a PCSK9 Inhibitor) Enhancing Chemoimmunotherapy as Neoadjuvant Treatment for Patients With pMMR\u002FMSS Locally Advanced Colon Adenocarcinoma (TRIUNITE-08)","TRIUNITE-08","Inclusion Criteria:\n\n* Signed the written informed consent form and voluntarily participate in the study.\n\nPathohistologically confirmed colon adenocarcinoma with cT3c stage or above. Aged 18 to 80 years, regardless of gender. The lower edge of the tumor is more than 10 cm from the anus. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Sufficient bone marrow, liver, kidney and coagulation functions assessed by laboratory tests (in accordance with the local laboratory reference range).\n\nNo previous anti-tumor treatment for the current colon cancer (including radiotherapy, chemotherapy, surgery, etc.).\n\nNo pregnancy or lactation for female patients; male patients agree to take effective contraceptive measures during the study.\n\nExclusion Criteria:\n\n* Previous anti-tumor treatment for the current colon cancer. Previous use of PCSK9 inhibitors or PD-1\u002FPD-L1 inhibitors. Active autoimmune diseases or a history of autoimmune diseases. Receiving immunosuppressant or systemic glucocorticoid therapy (except for local low-dose glucocorticoid use).\n\nActive infection requiring systemic anti-infective treatment. Severe cardiovascular diseases (e.g., severe hypertension, myocardial infarction, heart failure, etc.).\n\nComplicated primary tumor (e.g., tumor perforation, intestinal obstruction without relief after intervention).\n\nPregnant or lactating women. Other conditions that the investigator deems unfit for participation in the study (e.g., poor compliance, severe organ dysfunction, etc.).","80 Years",{"count":137,"type":21},106,[139],"PHASE2","This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab\u002FCapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR\u002FMSS locally advanced colon adenocarcinoma (cT3c+). 106 patients are 1:1 randomized to the combination or chemoimmunotherapy alone, with pCR as the primary endpoint.",[27],[143,144,145,146],"pMMR\u002FMSS","neoadjuvant immunochemotherapy","PCSK9 inhibitor","Tolecizumab","2026-03-09",{"date":149,"type":46},"2026-03-12",{"date":151,"type":21},"2026-04-10",{"date":153,"type":21},"2028-12-31",{"name":155,"class":53},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":126},"100580721","colon-erderly-low-dose-100580721","NCT06840977","COLON ERDERLY LOW DOSE","RETROSPECTIVE OBSERVATIONAL STUDY OF CHEMOTHERAPY IN ELDERLY PATIENTS IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER","CELOW","Inclusion Criteria:\n\n1. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.\n2. Age ≥ 70 years\n3. G8 score ≥ 12\n4. Patients with colorectal adenocarcinoma MSS\n5. Patients with BRAF WT colorectal adenocarcinoma\n6. Ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with MSI tumours\n2. Patients with BRAF V600E mutated tumours\n3. Patients not eligible for doublet chemotherapy by clinical decision","70 Years","99 Years",{"count":167,"type":21},51,"In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.",[27],[171,172,173,174],"metastatic colorectal adenocarcinom","low doses","chemotherapy","monoclonal antibodies","2026-01-30",{"date":177,"type":46},"2026-02-02",{"date":179,"type":21},"2026-02-01",{"date":181,"type":21},"2026-07-31",{"name":183,"class":53},"Matteo Clavarezza",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":16,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":126},"100620699","comparison-of-laparoscopic-and-open-total-mesocolic-excision-with-central-vascular-ligation-for-right-colon-carcinoma-100620699","NCT07361016","Comparison of Laparoscopic and Open Total Mesocolic Excision With Central Vascular Ligation for Right Colon Carcinoma","Inclusion Criteria:\n\n* rt cancer colon\n\nExclusion Criteria:\n\n* metastatisis","25 Years","65 Years",{"count":111,"type":21},[24],"The goal of this observational comparative study is to assess whether laparoscopic complete mesocolic excision with central vascular ligation (L-CME with CVL) provides improved short-term surgical outcomes compared with open complete mesocolic excision with central vascular ligation (O-CME with CVL) in patients with right-sided colon cancer.\n\nThe primary questions this study aims to answer are:\n\nDoes laparoscopic CME with CVL reduce blood loss, postoperative complications, and length of hospital stay compared with open CME?\n\nDoes laparoscopic CME with CVL achieve equivalent surgical specimen quality and short-term oncological outcomes compared to the open approach?\n\nResearchers compared laparoscopic versus open right hemicolectomy with CME and CVL in adult patients diagnosed with right colon cancer who were eligible for elective surgical resection.\n\nParticipants underwent standard preoperative assessment, including clinical evaluation, laboratory testing, imaging studies, colonoscopy, and biopsy confirmation. Surgical treatment consisted of either laparoscopic or open complete mesocolic excision with central vascular ligation, performed according to standardized oncologic surgical principles. Postoperative care followed an enhanced recovery protocol.\n\nPrimary outcome measures included operative time, intraoperative blood loss, time to first flatus, postoperative complications, and duration of hospital stay. Secondary outcomes included quality of the surgical specimen (lymph node yield, mesocolic integrity, and margin status) and short-term oncologic outcomes, including early recurrence during follow-up.",[196,27,197],"Right-sided Colon Cancer","Colorectal Neoplasms","2026-01-14",{"date":200,"type":46},"2026-01-22",{"date":202,"type":21},"2026-01",{"date":204,"type":21},"2027-12-31",{"name":206,"class":53},"Kafrelsheikh University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":230,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":126},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245","NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma",{"count":216,"type":21},341,[24],"The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[68,27,220,221,222,223,224,225,226,227,228,229],"Sentinel Lymph Node","Sentinel Lymph Node Biopsy","Colon Neoplasms","Colon Neoplasm","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Colon Surgery","Indocyanine Green (ICG)",[231,224,232,233,234,235,236],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","2025-11-17",{"date":239,"type":46},"2025-11-20",{"date":241,"type":46},"2024-12-12",{"date":243,"type":21},"2032-12-12",{"name":245,"class":53},"Meander Medical Center",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":126},"100453559","ldlt-in-non-resectable-colo-rectal-cancer-liver-metastasis-100453559","NCT05186116","LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis","Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: \"Trapianto di Fegato da Donatore Vivente Per Metastasi Epatiche Non Resecabili da Adenocarcinoma Del Colon\"]","LIVERMORE","Inclusion Criteria:\n\n* Age ≥18.\n* Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma.\n* Pathological classification of primary tumor as pT1-3, without peritoneal tumor deposits, absence of mucinous component \\>50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type.\n* No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET\u002FCT scans.\n* Liver metastases not eligible for curative liver resection\n* Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete \\[CR\\] or partial response \\[PR\\] or standard disease \\[SD\\]) during second- line treatment for at least 4 months.\n* Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant.\n* Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2.\n* Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Hereditary CRC syndromes including FAP (Familial adenomatous polyposis) and Lynch syndrome.\n* Prior extra hepatic metastatic disease or primary tumor local relapse.\n* Palliative resection of primary CRC tumor.\n* Disease progression\n* Other malignancies in the previous 5 years (with exception of in situ cervical carcinoma and basal cell carcinoma; superficial bladder tumors are allowed if curatively treated).\n* Active intra-venous or alcohol abusers (patients may be eligible if abstention \\> 6 months is demonstrated)\n* Active HIV infection\n* Psychiatric disorders and patient low compliance\n* Any reason why, in the judgment of the investigators, the patient should not participate (to be formally declared)","77 Years",{"count":256,"type":21},25,[24],"This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM.\n\nSecondary outcomes are graft survival and donor outcomes in terms of safety and quality of life.\n\nDonor selection is performed according to the currently used Institutional and National standards and protocols.",[27,260],"Liver Metastasis Colon Cancer",[262,263,264,265],"LDLT","living donor","CRLM","transplant oncology","2025-09-20",{"date":268,"type":46},"2025-09-25",{"date":270,"type":46},"2022-01-01",{"date":272,"type":21},"2032-01-01",{"name":274,"class":53},"Azienda Ospedaliero-Universitaria di Modena",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":126},"100582517","pilot-study-for-colorectal-cancer-and-advanced-adenoma-detection-with-the-mainz-biomed-colorectal-cancer-test-100582517","NCT06864338","Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test","Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test (eAArly DETECT)","eAArly DETECT","Group 1: Screening Group Inclusion Criteria\n\n1. Subject is any sex and ≥45 years of age\n2. Subject must be advised to have or be scheduled for a screening colonoscopy\n3. Subject is at average risk for colorectal cancer according to the United States Preventive Services Task Force (USPSTF) guidelines, including:\n\n   * no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease\n   * no family history of colorectal cancer (defined as one or more first degree relatives including parent, sibling, or child)\n   * no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer including:\n\n     * Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease\n     * Familial adenomatous polyposis (also referred to as \"FAP\", including attenuated FAP)\n     * Hereditary non-polyposis colorectal cancer syndrome (also referred to as \"HNPCC\" or \"Lynch Syndrome\")\n     * Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis\n     * Cronkhite Canada Syndrome\n4. Subject can understand the study procedures, and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form\n5. Subject is able and willing to provide stool samples within ninety (90) days before the colonoscopy procedure\n6. Subject is able and willing to undergo a colonoscopy after providing a stool sample Exclusion Criteria\n\n1\\. Subject had any precancerous findings on most recent colonoscopy. This does not include non-neoplastic polyps and\u002For hyperplastic polyps of any size (Note: tissue biopsies that result in no histopathology findings are acceptable) 2. Subject has a history of abnormal imaging suggesting colorectal cancer (e.g., colonography, MRI, CT, barium enema) 3. Subject has a history of any of the following cancers: oral, head and neck, lung, esophagus, gastric, biliary\u002Fliver, pancreatic, small bowel, or appendiceal 4. Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals\n\n* High-sensitivity fecal occult blood test or fecal immunochemical test within the previous twelve (12) months\n* sDNA-FIT test within the previous thirty-six (36) months 5. Subject has had a colonoscopy in the previous nine (9) years (not including failed\u002F aborted colonoscopy e.g., due to failed preparation, inability to reach the cecum, patient instability during the procedure, etc.) 6. Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease 7. Indication for colonoscopy due to overt rectal bleeding (e.g., hematochezia or melena) within the previous thirty (30) days (Note: blood on toilet paper, after wiping, does not constitute rectal bleeding) 8. Subject has any condition that in the opinion of the investigator should preclude participation in the study\n\nGroup 2: Diagnostic Group Inclusion Criteria\n\n1. Subject is any sex and ≥ 18 years of age\n2. Subject is able and willing to give informed consent\n3. Through imaging, a positive non-invasive screening test, or colonoscopy requiring additional intervention subject is suspected or known to have Colorectal Cancer or Advanced Adenoma\n4. Subject has not yet been treated (e.g., ablation, surgical resection, radiation, chemotherapy, etc.) and still has at least one intact or partially intact lesion\n5. Subject must have a diagnostic colonoscopy or surgical intervention scheduled within 90 days of sample collection\n6. Subject can understand the study procedures and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form\n7. Subject is able and willing to provide stool samples within ninety (90) days of enrollment and before any treatment procedures are initiated Exclusion Criteria\n\n1\\. Subject has had a tumor or malignancy other than colorectal cancer identified within the past five years (does not include non-melanoma skin cancer) 2. Subject has been previously diagnosed with inflammatory bowel disease (ulcerative colitis or Crohn's disease) 3. Subject has any condition that in the opinion of the investigator should preclude participation in the study",{"count":284,"type":21},2700,"The Mainz Biomed Colorectal Cancer Screening Test is being studied for its performance in the identification of the presence of colorectal cancer (CRC) or advanced adenoma (AA) in the colon in patients at average risk for colorectal cancer.",[287,288,27],"Colorectal Cancer Screening","Colorectal Cancer Metastatic",[290,291,292],"Stool test","Colorectal cancer screening test","advanced adenoma screeing test","2025-08-08",{"date":295,"type":46},"2025-08-12",{"date":297,"type":46},"2022-12-18",{"date":299,"type":21},"2025-11-30",{"name":301,"class":101},"Mainz Biomed",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":329},"100476329","phase-3-evaluating-novel-therapies-in-ctdna-positive-gi-cancers-100476329","NCT05482516","Evaluating Novel Therapies in ctDNA Positive GI Cancers","Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease","MRD-GI","Inclusion Criteria:\n\n1. Signed Informed Consent Form\n2. Age \\>= 18 years at time of signing Informed Consent Form\n3. Ability to comply with the study protocol, in the investigator's judgment\n4. Histologically or cytologically confirmed colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma, or extra-hepatic\u002Fintra-hepatic\u002Fgallbladder adenocarcinoma. Patients may be enrolled irrespective of any mutational analyses.\n5. Must have been diagnosed with any stage disease (including localized and metastatic disease) that was felt to have already been treated completely with curative-intent per investigator's, primary physician's, or research team's judgement. Curative-intent treatment strategies are unique to each tumor type and stage but includes all surgeries and perioperative therapies recommended. If patients were appropriately treated with curative intent but felt to be high-risk for relapse, they may be still be included.\n\n   o Patients diagnosed with hepatocellular carcinoma specifically must have Child Pugh A score at the time of screening; o Patients must have completed all definitive SOC treatment with curative intent (neoadjuvant, surgery, radiation, and adjuvant treatments) for specific tumor-type and stage per investigator's\u002Fprimary physician's or research team's judgment. Curative treatment regimens including chemotherapy, radiation, treatment sequencing, and surgery should have been followed as per local standards and NCCN guidelines or non-standard curative-intent therapy through a clinical trial at the discretion of the investigator\u002Ftreating physician.\n6. Patients who have undergone definitive, curative-intent treatment of oligometastatic (synchronous or metachronous) disease with NED per investigator judgement are acceptable for enrollment.\n7. Must have disease-free status documented by complete physical examination and imaging studies with no evidence of recurrent, residual, or metastatic disease on standard imaging (chest, abdomen, and pelvis captured by CT chest and CT or MRI of abdomen and pelvis) per investigator assessment within 28 days prior to enrollment\n8. Must have a tumor-specific ctDNA SignateraTM test with a positive result (any mean tumor molecule\u002FmL) drawn within 1 year of completing all curative-intent treatment and within 28 days prior to enrollment. In the setting of a negative scan for recurrence, this will be defined as subclinical molecular disease.\n9. ECOG Performance Status of 0-2\n10. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 28 days prior to initiation of study treatment:\n\n    * ANC ≥1.5 x 109\u002FL (1500\u002FuL) without granulocyte colony-stimulating factor support\n    * Lymphocyte count ≥ 0.5 x 10\\^9\u002FL (500\u002FuL)\n    * Platelet count ≥ 75 x 10\\^9\u002FL (75,000\u002FuL) without transfusion\n    * Hemoglobin ≥ 90 g\u002FL (9 g\u002FdL) Patients may be transfused to meet this criterion.\n    * AST, ALT, and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN)\n    * Note: for HCC, AST, ALT, and alkaline phosphatase (ALP) ≤ 5 x upper limit of normal (ULN)\n    * Serum bilirubin ≤ 1.5 x ULN with the following exception: Patients with known Gilbert disease or HCC: serum bilirubin ≤3 x ULN\n    * Serum creatinine ≤ 1.5 x ULN or Creatinine clearance ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n    * Urine dipstick for proteinuria \\\u003C 2 + (if ≥ 2+ proteinuria on dipstick urinalysis, patient should undergo 24-hour urine collection and must demonstrate \\\u003C 1 g protein in 24 hours).\n    * Serum albumin ≥ 25 g\u002FL (2.5 g\u002FdL). Cut-off of ≥ 28 g\u002FL (2.8 g\u002FdL) will be used for HCC patients.\n    * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN. Note: for HCC patients INR or aPTT should be ≤ 2 x ULN.\n11. For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n12. Negative HIV test at screening, with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ≥ 200µL, and have an undetectable viral load.\n13. Select patients with well compensated, treated HBV infection and chronic HCV infection may be considered\n14. Women of childbearing potential must have a negative serum test result within 28 days prior to initiation of study treatment. If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.\n15. Women must not be breastfeeding.\n16. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs as defined below: o Women must remain abstinent or use contraceptive methods with a failure rate of \\\u003C 1% per year during the treatment period and for at least 5 months after the final dose of atezolizumab and for 6 months after the last dose of bevacizumab. o Women must refrain from donating eggs during this same period. o A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.\n17. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: o With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for 6 months after the final dose of bevacizumab. Men must refrain from donating sperm during this same period. o With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of bevacizumab to avoid exposing the embryo. o The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n\nExclusion Criteria:\n\n1. There is suspicion or evidence of gross residual, recurrent, or metastatic disease present on physical exam, imaging, or by biopsy within 28 days of starting study treatment.\n2. Patients who were\u002Fare eligible for but have not received all guideline-recommended standard of care therapy within the recommended time-frame for definitive treatment. The exception (permitting inclusion) would be if any standard of care treatment was deferred due to valid medical reasoning based on the investigator's discretion or patient's preference.\n3. Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis (see Appendix 6 for a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions: o Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study. o Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. o Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met: - Rash must cover \\\u003C 10% of body surface area; - Disease is well controlled at baseline and requires only low-potency topical corticosteroids; - No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months\n4. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n5. Active tuberculosis\n6. Clinically significant cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to study treatment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment.\n7. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to randomization.\n8. Inadequately controlled hypertension (defined as systolic blood pressure \\>150mmHg and\u002For diastolic blood pressure \\>100 mmHg), based on an average of ≥ 3 BP blood pressure readings on ≥ 2 sessions. Anti-hypertensive therapy to achieve these parameters is allowable.\n9. History of hypertensive crisis or hypertensive encephalopathy\n10. History of Grade ≥ 4 venous thromboembolism\n11. History or evidence upon physical or neurological examination of central nervous system bleed\n12. History of Grade ≥ 2 hemoptysis (defined as ≥ 2.5 mL of bright red blood per episode) within 1 month prior to screening.\n13. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).\n14. Current or recent (\\\u003C10 days prior to initiation of study treatment) use of aspirin (\\>325 mg\u002Fday), or clopidogrel (\\>75 mg\u002Fday) Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the INR and\u002For aPTT is within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for ≥ 2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. For prophylactic use of anticoagulants or thrombolytic therapies, local label approved dose levels may be used. The use of direct oral anticoagulant therapies such as dabigatran (Pradaxa) and rivaroxaban (Xarelto) is not recommended due to bleeding risk.\n15. Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID); o Occasional use of NSAIDs for the symptomatic relief of medical conditions such as headache or joint pain is allowed.\n16. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to initiation of study treatment, or anticipation of need for major surgical procedure during the course of the study.\n17. Local therapy to liver or other organ (e.g. radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization, etc.) within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure.\n18. Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or high risk for bleeding in high-risk patients (patients with HCC, cirrhosis, or other conditions predisposing patients to high-risks of portal hypertension).\n19. High risk patients must undergo an esophagogastroduodenoscopy (EGD) and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD within 6 months prior to initiation of study treatment do not need to repeat the procedure.\n20. A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment\n21. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to initiation of study treatment.\n22. Placement of a vascular access device should be at least 2 days prior to initiation of study treatment.\n23. Active infection requiring IV antibiotics at the time of initiation of study treatment.\n24. Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety\n25. History of abdominal fistula, GI perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to study treatment. o If GI bleeding was from a lesion or a condition that was appropriately treated and patient is deemed to be low risk for recurrent GI bleed per investigator judgement, enrollment will be allowed.\n26. Serious, non-healing wound, active ulcer, or untreated bone fracture\n27. Subjects with previous malignancies (separate from the malignancy for which patient is being enrolled) are excluded. Exceptions include another malignancy for which a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period. Other exceptions include malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, Stage I uterine cancer or others based on the physician\u002Finvestigator's discretion.\n28. Prior allogeneic stem cell or solid organ transplantation\n29. Any other disease, active infection, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n30. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab\n31. Treatment with investigational therapy within 28 days prior to initiation of study treatment\n32. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n33. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \\[IL-2\\]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment\n34. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions: o Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained. o Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n35. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n36. Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation\n37. Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab or 6 months after the final dose of bevacizumab.\n\n    Women of childbearing potential must have a negative serum or urine pregnancy test result within 28 days prior to initiation of study treatment.\n38. Uncontrolled or symptomatic hypercalcemia (ionized calcium \\> 1.5 mmol\u002FL, calcium \\> 12 mg\u002FdL or corrected serum calcium \\> ULN)\n39. History of leptomeningeal disease\n40. Uncontrolled tumor-related pain\n41. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); Patients with indwelling catheters (e.g., PleurX) are allowed.\n42. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases. Brain scans are not required to be performed at screening but can be done at the clinician's or investigator's discretion depending on clinical history. Asymptomatic patients with previous definitively (with curative-intent) treated CNS lesions that are believed to have no evidence of residual disease per investigator judgement are eligible, provided that all of the following criteria are met: - The patient has no history of intracranial hemorrhage or spinal cord hemorrhage; - The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment.; - The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. - If the patient is receiving anti-convulsant therapy, the dose is considered stable.",{"count":311,"type":21},20,[89],"This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC\u002Fintra-hepatic-\u002Fextra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers. These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuvant, surgery, local therapies, and\u002For adjuvant therapy as applicable), as defined by the treating primary physician or research team, with curative intent but have a positive SignateraTM tumor-informed ctDNA test and NED radiographically by standard imaging within 28 days prior to enrollment and within 1 year of completing all curative-intent therapy. All patients will be treated with intravenous (IV) atezolizumab 1200 mg IV and bevacizumab 15 mg\u002Fkg on Day 1 of 21-day cycles until disease recurrence, ctDNA POD, unacceptable toxicity, or subject withdrawal of consent with a maximum 12 month total duration of study therapy. Atezolizumab and bevacizumab drug will be provided.",[27,29,315,316,317,318,319],"Gastric Adenocarcinoma","Pancreatic Adenocarcinoma","Hepatocellular Carcinoma","Adenocarcinoma of Biliary Tract","Gallbladder Adenocarcinoma","2025-05-20",{"date":322,"type":46},"2025-05-22",{"date":324,"type":46},"2023-03-29",{"date":326,"type":21},"2028-12",{"name":328,"class":53},"Georgetown University",3,{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":359},"100590721","current-microsatellite-stability-results-in-colon-cancer-100590721","NCT06971107","Current Microsatellite Stability Results in Colon Cancer","TKRCD-MSI Study: Current Microsatellite Stability Findings in Colon Cancer - Nationwide Experience From Turkey","Inclusion Criteria:\n\nPatients who have undergone curative-intent surgery for colon adenocarcinoma between June 1, 2025, and May 31, 2026 Surgery performed at a center with \\>30 colon cancer surgeries per year Availability of MMR protein immunohistochemistry (IHC) and\u002For MSI test results from resection specimen and\u002For preoperative endoscopic biopsy Signed informed consent for participation and data collection\n\nExclusion Criteria:\n\nNon-adenocarcinoma malignancies of the colon (e.g., neuroendocrine tumors, lymphomas) Rectal cancers (defined as tumors within 15 cm of the anal verge on endoscopy or MRI) Incomplete medical or pathological records preventing classification of MMR status",{"count":338,"type":21},1500,"The goal of this prospective observational study is to learn more about how a specific type of DNA repair issue-called mismatch repair deficiency (dMMR)-affects colon cancer in people living in Turkey. The study will look at how often dMMR occurs, how it is reported, and how it relates to treatment outcomes.\n\nThe main questions it aims to answer are:\n\n* How common is dMMR in colon cancer, and does it vary by where the tumor is in the colon?\n* How often is MSI (microsatellite instability) status reported in colon cancer biopsy reports before surgery?\n* How do different types of dMMR (such as MLH1\u002FPMS2 loss, MSH2\u002FMSH6 loss, or sporadic cases) affect survival over three years?\n\nParticipants will:\n\n* Be people who had surgery for colon cancer between June 1, 2025 and May 31, 2026 at hospitals in Turkey that treat more than 30 colon cancer cases each year.\n* Have their medical and pathology data reviewed, including information about tumor location, biopsy results, surgery, and treatment.\n\nThis study will not involve any new treatments. Instead, it will use existing medical records to better understand how to improve care and identify people who may benefit from immunotherapy. Results from this study will be shared at scientific meetings and published in medical journals.",[27,341,342],"MSI Positive Colorectal Cancer","MSI Negative Colorectal Cancer",[197,344,345,346,347,348,349],"Microstaellite Instability","DNA Mismatch Repair","Immunohistochemistry","Prognosis","Survival Analysis","Epidemiologic Methods","2025-05-06",{"date":352,"type":46},"2025-05-14",{"date":354,"type":21},"2025-06-01",{"date":356,"type":21},"2029-05-31",{"name":358,"class":53},"Turkish Society of Colon and Rectal Surgery",2,{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":16,"sex":17,"minAge":367,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":372,"conditions":373,"keywords":379,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":359},"100570160","evaluation-of-prevecols-efficiency-as-a-second-line-method-for-the-early-colorectal-cancer-detection-100570160","NCT06703632","Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection","MS-Prevecol","Inclusion Criteria:\n\n* Participants ages from 50 to 69 years (both included) at the time of informed consent signed.\n* Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.\n* Participants with a positive result of FIT\u002FFOBT analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a regular procedure of the colorectal cancer screening programme.\n* Participants asymptomatic, average risk for CRC. Average risk is defined as those individuals who are age 50 or over with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family history of CRC (first degree relatives).\n\nExclusion Criteria:\n\n* Participants who have developed any another type of cancer in the 5 years prior to their participation in the study.\n* Participants who have previously received chemotherapy or radiotherapy (5 years).\n* Participants previously or currently diagnosed with Familiar Adenomatous Polyposis or Lynch Syndrome or Inflammatory Bowel Disease.\n* Inadequate intestinal preparation for colonoscopy with BBPS score ≤1 in any colon section, excluding diagnostic of CRC.\n* Participants who have undergone polypectomy in the previous 5 years.\n* Hemolysis of blood sample or absence of blood sample.\n* Participants who are arrested at judicial or official request\n* Participants who are in a dependent personal or non-medical relationship with the Sponsor or the investigator.","50 Years","69 Years",{"count":370,"type":21},4538,[24],"The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are:\n\n* Values of efficacy, efficiency, impact and safety of PreveCol.\n* Values of preferences of participants for screening methods.\n* Values of PREMs into screening programme.\n\nParticipants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.",[374,375,376,377,27,378],"Screening for Colon Cancer","Blood Samples","Survey and Questionnaire","Colorectal Carcinoma","Precancerous Lesion of Colon",[380,381,382,383,384],"colorectal cancer","screening programme","liquid biopsy","second line","questionnaire","2025-02-25",{"date":387,"type":46},"2025-02-27",{"date":389,"type":46},"2025-01-14",{"date":391,"type":21},"2025-12",{"name":393,"class":101},"ADVANCED MARKER DISCOVERY S.L.",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":408,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":329},"100565283","phase-2-encorafenib--cetuximab-beyond-progression-in-combination-with-folfiri-in-patients-with-braf-v600e-mutated-metastatic-colorectal-cancer-progressing-on-encorafenib--cetuximab-100565283","NCT06640166","Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","ECLYPse","Inclusion Criteria:\n\n* written informed consent to study procedures;\n* age ≥ 18 years;\n* histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma;\n* radiological evidence of metastatic disease;\n* evidence of measurable disease according to RECIST 1.1 criteria;\n* presence of BRAF V600E mutation in tumor tissue (primary CRC and\u002For related metastasis) as previously determined by a local assay at any time prior to screening (only PCR and NGS-based local assays results will be acceptable);\n* disease progression while on treatment with EC received in 2nd line setting\n\n  * EC administered after disease relapse during treatment or within 6 months following adjuvant therapy will be second line;\n  * maintenance therapy given in the metastatic setting after a first line doublet or triplet chemotherapy will not be considered a separate regimen;\n* best response to previous treatment with EC: CR, PR or SD lasting for at least 3 months.\n* patient fit for a subsequent treatment line with FOLFIRI. Patients exposed to irinotecan and fluoropyrimidines during previous line for metastatic disease are eligible, provided that the patient has recovered from G3 toxicity;\n* life expectancy ≥ 3 months;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤1.\n* Adequate bone marrow function at screening:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n  * Platelets ≥ 100 × 10\\^9\u002FL;\n  * Hemoglobin ≥ 9.0 g\u002FdL;\n  * Note: Transfusions will be allowed to achieve this. Transfusions will be permitted provided that the patient has not received more than 2 units red blood cells in the prior 4 weeks to achieve this criteria.\n* Adequate renal function at screening: serum creatinine ≤ 1.5 × upper limit of normal (ULN), or calculated by Cockroft-Gault formula, or directly measured creatinine clearance ≥ 50 mL\u002Fmin at screening.\n* Adequate hepatic function at screening:\n\n  * serum total bilirubin ≤ 1.5 × ULN;\n  * alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in presence of liver metastases.\n* Adequate cardiac function characterized by the following at screening: QT interval corrected for heart rate using Fridericia's formula (QTcF) value ≤480 msec.\n* Availability of treatment-naïve, archival FFPE tumor tissue sample.\n* Ability to take oral medications.\n* Male subjects with female partners of childbearing potential must be willing to use adequate contraception, starting with the first dose of study therapy through 180 days after the last dose of treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* Women of childbearing potential must have a negative blood or urine pregnancy test at the baseline visit.\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study starting with the first dose of study therapy through 180 days after the last dose of treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* Will and ability to comply with the protocol.\n\nExclusion Criteria:\n\n* patients experiencing PD as best response to EC;\n* patients with specific BRAFi\u002FAntiEGFR contraindications;\n* patients with specific irinotecan or fluoropyrimidines contraindications;\n* patients with DPYD deficiency;\n* life expectancy ≤3 months;\n* ECOG PS \\>1.\n* Any of the following in the 6 months prior to treatment start: myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft \\[CABG\\], coronary angioplasty or stenting), congestive heart failure (≥ New York Heart Association Classification Class II), serious cardiac arrhythmia (except atrial fibrillation and appropriately controlled paroxysmal supraventricular tachycardia), cerebrovascular accident, symptomatic pulmonary embolism.\n* Congenital long QT syndrome.\n* Impaired gastrointestinal function or disease that may significantly alter the absorption of encorafenib (uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption).\n* Uncontrolled coagulopathy.\n* Patients has a known history of Gilbert's syndrome or is known to have any of the following genotypes: UGT1A1\\*6\u002F\\*6, UGT1A1\\*28\u002F\\*28, or UGT1A1\\*6\u002F\\*28.\n* Active infection requiring systemic therapy.\n* Known history of acute or chronic pancreatitis.\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).\n* Symptomatic brain metastasis or leptomeningeal disease. Prior hypersensitivity or toxicity that would suggest an inability to tolerate administration of the planned dose of investigational products.\n* Residual CTCAE \\> Grade 2 toxicity from any prior anticancer therapy, with the exception of alopecia or neuropathy.\n* Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies, including current treatment with a non-topical medication known to be a strong inhibitor of cytochrome P450 (CYP) 3A4 ≤ 1 week prior to the start of study treatment.\n* Concomitant use of St. John's Wort (hypericum perforatum).\n* Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study.\n* Concurrent or previous other malignancy within the past 3 years, with the exception of effectively treated squamous cell or basal cell skin cancer, melanoma in situ, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, carcinoma in situ of the colon or rectum, or other noninvasive or indolent malignancy without Sponsor approval.\n* Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study and until 180 days after the last trial treatment.",{"count":256,"type":21},[139],"The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.",[377,197,405,28,406,116,68,27,407,223],"Colorectal Tumor","Colorectal Cancer (CRC)","Colon Carcinoma",[409,410,411,412,380,413,414],"BRAF","V600E","encorafenib","cetuximab","FOLFIRI","BRAF V600E","2025-02-11",{"date":417,"type":46},"2025-02-12",{"date":419,"type":46},"2024-06-03",{"date":421,"type":21},"2026-06-30",{"name":423,"class":53},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":126},"100570641","phase-2-hdac-inhibitor-combination-with-chemoimmunotherapy-in-the-neoadjuvant-treatment-of-pmmr-locally-advanced-colon-cancer-100570641","NCT06709885","HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer","HDAC Inhibitor Combination With Immunochemotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: A Multicenter, Double-arm, Phase II Randomized Controlled Study","Inclusion Criteria:\n\n1. Signed written informed consent to voluntarily join this study\n2. Patients with colon cancer who are assessed by abdominal contrast-enhanced CT\u002Fabdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly invades or adheres to adjacent organs or structures).\n3. Adenocarcinoma of the colon confirmed by histopathological examination.\n4. At least 18 years old, male or female.\n5. Uncomplicated primary tumors (Perforation ； obstruction and bleeding that cannot be relieved by intervention)\n6. The lower edge of the tumor is more than 12cm away from the anus.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Adequate bone marrow, liver, renal, and coagulation function as assessed by the laboratory as required by the protocol\n9. Have not received any anti-tumor therapy for cancer in the past, including radiotherapy, chemotherapy, surgery, etc.;\n\nExclusion Criteria:\n\n1. History of previous allergy to monoclonal antibodies, any component of HDACi, and capecitabine;\n2. Has received or is receiving any of the following treatments in the past:\n\n   1. Received any treatment against the mechanism of action of tumor immunity, such as immunization, HDACi, etc.\n   2. Immunosuppressive drugs, or systemic hormonal drugs within 2 weeks prior to the first use of the study drug to achieve immunosuppressive purposes\n   3. Receipt of a live attenuated vaccine within 4 weeks prior to the first use of study drug;\n   4. Major surgery or severe trauma within 4 weeks prior to the first use of study drug;\n   5. Receipt of systemic non-specific immunomodulatory therapy within 2 weeks prior to the first dose; Have received Chinese herbal medicines or proprietary Chinese medicines with anti-tumor indications within 2 weeks before the first dose.\n3. Has any active autoimmune disease or history of autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism,\n4. dMMR\u002FMSI-H;\n5. Presence of cardiac clinical symptoms or diseases that are not well controlled,\n6. Severe infection (CTCAE \\> grade 2) within 4 weeks prior to the first use of study drug, with active tuberculosis infection found by medical history or CT examination,\n7. Presence of active hepatitis B, hepatitis C 8.5 years of diagnosis of other malignant tumors, (adequately treated basal cell carcinoma of the skin or squamous cell skin cancer or carcinoma in situ of the cervix, etc., can be considered for enrollment);\n\n9\\. Pregnant or lactating females; 10. As judged by the investigator, there are other factors that may lead to forced termination of the study, such as other serious diseases (including mental illnesses) requiring concomitant treatment, alcoholism, drug abuse, family or social factors, and factors that may affect the safety or compliance of the subject.\n\n11\\. Have a history of immunodeficiency, including a positive HIV test, or have other acquired or congenital immunodeficiency disorders, or have a history of organ transplantation or allogeneic bone marrow transplantation;",{"count":432,"type":21},100,[139],"The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.\n\nThe main questions it aims to answer are:\n\nCan HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?",[27],[437,143,144,438,439],"HDAC inhibitors","Oxaliplatin","Capecitabine","2024-11-25",{"date":442,"type":46},"2024-11-29",{"date":444,"type":46},"2024-10-15",{"date":446,"type":21},"2027-09-30",{"name":155,"class":53}]